Achieve Life Sciences (ACHV) Shares Outstanding (Weighted Average) (2010 - 2026)

Achieve Life Sciences has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $16.3 million for Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 11308.73% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 11308.73% YoY) and the FY2025 annual result came in at $43.6 million, up 35.93% from the prior year.
• Shares Outstanding (Weighted Average) declined to $16.3 million in Q1 2026, from $43.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $43.6 million in Q4 2025 and troughed at $24375.0 in Q3 2023.
• A 5-year average of $16.3 million and a median of $16.3 million in 2026 frame the typical range for Shares Outstanding (Weighted Average).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) sank 99.75% — and 2024, when it soared 128113.32%.
• Tracing ACHV's Shares Outstanding (Weighted Average) over 5 years: stood at $10.6 million in 2022, then soared by 87.18% to $19.8 million in 2023, then soared by 61.75% to $32.1 million in 2024, then soared by 35.93% to $43.6 million in 2025, then slumped by 62.61% to $16.3 million in 2026.
• Business Quant data shows ACHV's Shares Outstanding (Weighted Average) at $16.3 million in Q1 2026, $43.6 million in Q4 2025, and $16.7 million in Q3 2025.